PRODUCT DESCRIPTION:

Medroxyprogesterone Acetate & Estradiol Cypionate Injection is a combined long-acting injectable contraceptive, offering extended protection through a synergistic blend of progestin and estrogen. Medroxyprogesterone Acetate provides potent ovulation suppression, while Estradiol Cypionate stabilizes the endometrium and improves menstrual cycle control.

Presented as a lyophilized powder with solvent, this formulation ensures stability, longer shelf life, and reconstitution accuracy, making it ideal for institutional, public health, and gynecology-based use. It is typically administered once every 28–30 days under medical supervision.

Formulation & Presentation:

• Dosage Form: Tablets
• Presentation: Lyophilized Powder With Solvent
• Available Strengths
  • Medroxyprogesterone Acetate 120 MG
  • Estradiol Cypionate 10 MG
• Route of Administration: Oral (As per physician’s discretion or therapeutic indication)

Therapeutic Indications:

• Long-term hormonal contraception
• Menstrual irregularities requiring hormonal regulation
• Adjunct therapy for women requiring estrogen-progestin support (under physician direction)
• Suitable for reproductive-age women seeking a non-daily contraceptive option

Side Effects:

• COMMON: Irregular menstrual bleeding or spotting, Headache, Breast tenderness, Nausea, Injection site reactions
• SERIOUS (RARE): Venous thromboembolism (VTE), Liver dysfunction, Mood changes or depressive symptoms, Bone mineral density reduction (with prolonged progestin use)
• PRECAUTIONS: Contraindicated during pregnancy or in women with undiagnosed vaginal bleeding
  • Not suitable for women with a history of thromboembolic disorders or estrogen-sensitive cancers
  • Long-term use should be accompanied by monitoring of bone health and liver function
  • Should only be administered under medical supervision with appropriate screening
  • Does not offer protection against HIV or other sexually transmitted infections